【目的】探讨Ｂｃｌ－２、ｐ５３在良恶性骨肿瘤组织中的蛋白表达情况及其生物学意义。【方法】应用ＡＢＣ免疫组化方法对３３例恶性骨肿瘤，包括１９例骨肉瘤，１４例软骨肉瘤和２２例良性骨肿瘤（骨软骨瘤）组织中Ｂｃｌ－２，ｐ５３的蛋白表达进行研究。【结果】恶性骨肿瘤组织中Ｂｃｌ－２，ｐ５３蛋白的阳性表达率分别为５１．５％和５４．５％，其中骨肉瘤组织为６３．２％和４７．４％，软骨肉瘤组织为３５．７％和６４．３％；良性骨肿瘤组织阳性表达率为１８．２％和２２．７％。恶性骨肿瘤组织Ｂｃｌ－２，ｐ５３蛋白阳性表达率明显高于良性骨肿瘤（Ｐ＜０．０５），骨肉瘤组织Ｂｃｌ－２蛋白阳性表达率明显高于骨软骨瘤（Ｐ＜０．０１），软骨肉瘤组织ｐ５３蛋白阳性率明显高于骨软骨瘤（Ｐ＜００５）。ＡＫＰ值增高组的恶性骨肿瘤组织ｐ５３蛋白阳性表达率（７５％）明显高于ＡＫＰ值正常值组（２０％，Ｐ＜０．０５）。【结论】Ｂｃｌ－２癌基因介导的凋亡紊乱和ｐ５３肿瘤抑制基因突变失活与恶性肿瘤的发生有关，Ｂｃｌ－２蛋白表达活性可能与骨肿瘤的恶性程度有关，ｐ５３肿瘤抑制基因突变失活是恶性肿瘤细胞成骨活性增强的因素之一。标记羊抗鼠ＩｇＧ和ＡＢＣ试剂，购自Ｓｉｇｍａ公? 【Objective】 To investigate the protein expression and biological significance of Bcl-2 and p53 in benign and malignant bone tumors. 【Methods】 The protein expression of Bcl-2 and p53 in 33 malignant bone tumors, including 19 osteosarcomas, 14 chondrosarcomas, and 22 benign bone tumors (osteochondromas) were studied by ABC immunohistochemistry. 【Results】 The positive expression rate of Bcl-2 and p53 protein in malignant bone tumors were 51.5% and 54.5%, respectively, among which osteosarcoma tissues were 63.2% and 47.4%, and chondrosarcoma tissues were 35. 7% and 64.3%; The positive expression rate of benign bone tumors was 18.2% and 22.7%. The positive rate of Bcl-2 and p53 protein expression in malignant bone tumors was significantly higher than that of benign bone tumors (P<0.05). The positive expression rate of Bcl-2 protein in osteosarcoma tissue was significantly higher than that in osteochondroma (P<0.01). The positive rate of p53 protein in chondrosarcoma tissue was significantly higher than that in osteochondroma (P<005). The positive expression rate of p53 protein in malignant bone tumor tissues (75%) was significantly higher in AKP values ​​than in normal AKP values ​​(20%, P<0.05). 【Conclusion】 Bcl-2 oncogene-mediated apoptosis inactivation and p53 tumor suppressor gene mutation inactivation are associated with the development of malignant tumors. Bcl-2 protein expression activity may be related to the degree of malignancy of bone tumors. p53 tumor suppressor gene mutations are lost. Livelihood is one of the factors that enhance the osteogenic activity of malignant tumor cells. Labeled goat anti-mouse IgG and ABC reagents purchased from Sigma Corporation